Should You Buy Shares in Galderma or NVIDIA in 2025?

Whatever age you are, if you currently own an aesthetic business, you'll probably be investing some money into tax-efficient vehicles such as a SIPP and a Stocks and Shares ISA to provide a future source of income.

It's very fashionable to drip-feed money every month into index tracker funds rather than pick individual shares. However, although it's riskier, it can be worth taking a percentage of your savings and investing them in individual shares to enhance the growth of your investments.

If you're going to do this, I personally like the advice of Peter Lynch, who managed the Magellan Fund for Fidelity, which annualized a return of double the S&P 500 over 13 years. He also wrote the bestselling retail investment books One Up on Wall Street and Beating the Street.

Although many of the companies operating in the aesthetic sector are not listed on stock exchanges or are part of much larger companies, there are some well-known suppliers where it's possible to buy shares. In this video I review the recent share price growth of the Dermatology company Galderma, who supply injectable products include Restylane, Sculptra and Azzalure and Alluzience and compare this to tech stock NVIDIA.